Down-regulation of HIF-1α by oncolytic reovirus infection independently of VHL and p53

Cancer Gene Therapy

Volumn 17, Issue 5, 2010, Pages 365-372

  Cho, I R ^a   Koh, S S ^b   Min, H J ^b   Park, E H ^a   Ratakorn, S ^a   Jhun, B H ^a   Jeong, S H ^c   Yoo, Y H ^c   Youn, H D ^d   Johnston, R N ^e   Chung, Y H ^a  

^a Pusan National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Dong A University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

Hypoxic inducible factor 1a; Renal carcinoma; Reovirus; Von Hippel Lindau (VHL); YC 1

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; HYPOXIA INDUCIBLE FACTOR 1; ONCOLYTIC VIRUS; PROTEIN P53; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSCRIPTION; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; VIRUS INFECTION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; DOWN-REGULATION; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; ONCOLYTIC VIRUSES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

ORTHOREOVIRUS;

EID: 77951098753     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.84     Document Type: Article

References (40)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276.
2. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev 2004; 4: 437-447.
3. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004; 26: 262-269.
4. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (New York, NY) 2001; 292: 468-472.
5. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
6. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19: 4298-4309.
7. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras\RalGEF\p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad SciUSAm 2004; 101: 11099-11104.
8. Kim M, Chung YH, Johnston RN. Reovirus and tumor oncolysis. J Microbiol (Seoul, Korea) 2007; 45: 187-192.
9. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963; 77: 29-37.
10. Nibert ML, Schiff LA, Fields BN. Mammalian reoviruses contain a myristoylated structural protein. J Virol 1991; 65: 1960-1967.
11. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science (New York, NY) 1998; 282: 1332-1334.
12. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63: 348-353.
13. Park EH, Koh SS, Srisuttee R, Cho IR, Min HJ, Jhun BH et al. Expression of HBX, an oncoprotein of hepatitis B virus, blocks reoviral oncolysis of hepatocellular carcinoma cells. Cancer Gene Ther 2009; 16: 453-461.
14. Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004; 10: 8561-8576.
15. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83(Part 3): 491-502.
16. Russel FG, Masereeuw R, van Aubel RA. Molecular aspects of renal anionic drug transport. Ann Rev Physiol 2002; 64: 563-594.
17. Norman KL, Lee PW. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 2005; 10: 847-855.
18. Ikeda Y, Nishimura G, Yanoma S, Kubota A, Furukawa M, Tsukuda M. Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris, Nasus, Larynx 2004; 31: 407-412.
19. Janssen HL, Higuchi H, Abdulkarim A, Gores GJ. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1\death receptor 4 expression. J Hepatol 2003; 39: 414-420.
20. Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 2001; 20: 6910-6919.
21. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997; 320: 161-166.
22. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001; 61: 947-954.
23. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS et al. YC-1: a potential anticancer drug targeting hypoxia-induci-ble factor 1. J Natl Cancer Inst 2003; 95: 516-525.
24. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803-811.
25. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y et al. Reovirus therapy of lymphoid malignancies. Blood 2002; 100: 4146-4153.
26. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-indepen-dent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006; 26: 2019-2028.
27. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10: 5772-5781.
28. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
29. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22: 395-405.
30. Kim HY, Kim YH, Nam BH, Kong HJ, Kim HH, Kim YJ et al. HIF-1alpha expression in response to lipopolysaccaride mediates induction of hepatic inflammatory cytokine TNFal-pha. Exp Cell Res 2007; 313: 1866-1876.
31. Yoo YG, Oh SH, Park ES, Cho H, Lee N, Park H et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem 2003; 278: 39076-39084.
32. Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol 2004; 24: 5223-5234.
33. Cheng J, Kang X, Zhang S, Yeh ET. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007; 131: 584-595.
34. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 2007; 25: 207-217.
35. Hwang II, Watson IR, Der SD, Ohh M. Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol 2006; 80: 10712-10723.
36. Dang DT, Chen F, Gardner LB, Cummins JM, Rago C Bunz F et al. Hypoxia-inducible factor-1alpha promote nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 2006; 66: 1684-1936.
37. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation J Natl Cancer Inst 2004; 96: 946-956.
38. Escuin D, Kline ER, Giannakakou P. Both microtubule stabilizing and microtubule-destabilizing drugs inhibit hy poxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005; 65 9021-9028.
39. Welsh SJ, Williams RR, Birmingham A, Newman DJ Kirkpatrick DL, Powis G. The thioredoxin redox inhibitor 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibi hypoxia-induced factor 1alpha and vascular endothelia growth factor formation. Mol Cancer Ther 2003; 2: 235-243
40. Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH et al. YC-1 inhibits HIF-1 expression in prostate cance cells: contribution of Akt\NF-kappaB signaling to HIF 1alpha accumulation during hypoxia. Oncogene 2007; 26 3941-3951.